Salix Pharmaceuticals, Ltd.

383 articles with Salix Pharmaceuticals, Ltd.

• Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022

  5/18/2022

  Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022.

• Salix Brings Educational Resources on Constipation Into the Homes of Patients and Caregivers for Constipation Awareness Month

  12/3/2021

  Bausch Health Companies Inc. today introduced a collection of digital and social activations aimed at helping adult patients with opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

• Salix Will Share New Rifaximin Data At AASLD's The Liver Meeting™ 2021

  11/11/2021

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals announced two abstracts featuring new data for rifaximin are being presented at The Liver Meeting™ 2021, organized by the American Association for the Study of Liver Diseases, which is taking place virtually Nov. 12-15, 2021.

• Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific Meeting

  10/25/2021

  Research Findings for XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and RELISTOR® (methylnaltrexone bromide) Will be Presented

• New Report Reveals Barriers To Quality Care For Chronic Liver Disease Patients, A Cause Of Morbidity And Mortality Projected To Grow In The United States

  10/25/2021

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal and liver diseases, released key findings from a survey of health care providers treating chronic liver disease, including potential gaps in prevention and diagnosis efforts.

• Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021

  9/2/2021

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, announced that new Health Economic Outcomes Research data featuring RELISTOR® will be shared at PAINWeek 2021 taking place in Las Vegas from Sept.

• Salix Announces 2021 Gastrointestinal Health Scholars Program Winners

  7/22/2021

   Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, today announced the winners of its 2021 Salix Gastrointestinal Health Scholars Program.

• Salix Will Feature New Data At Digestive Disease Week® 2021

  5/17/2021

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, announced four scientific poster presentations featuring data for XIFAXAN®, TRULANCE® and PLENVU® to be shared at Digestive Disease Week® 2021, which takes place virtually May 21-23, 2021.

• Salix Announces 2021 Gastrointestinal Health Scholars Program

  2/18/2021

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, announced the opening of the application period for the 2021 Salix Gastrointestinal Health Scholars Program.

• Salix To Present Data At AASLD's The Liver Meeting Digital Experience

  11/11/2020

  Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology (GI) business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointes

• Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeting

  10/22/2020

  Bausch Health Companies Inc and Salix Pharmaceuticals announced 11 scientific posters presenting data that span Salix's portfolio at the American College of Gastroenterology 2020 Virtual Annual Scientific Meeting, taking place Oct. 23-28, 2020.

• Salix To Present Clinical Data At United European Gastroenterology Week Virtual 2020

  10/8/2020

   Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointesti

• Salix Supports Liver Awareness Month With New Educational Initiatives

  10/5/2020

  Educational Online Resource Offers Tools for Early Detection of Overt Hepatic Encephalopathy in Chronic Liver Disease Patients

• Salix To Highlight New Data Across Its Portfolio Of Products At Digestive Disease Week 2020 Virtual Meeting

  4/30/2020

  Bausch Health Companies Inc. and Salix Pharmaceuticals announced that fourteen new scientific posters featuring research and data spanning Salix's GI portfolio – including rifaximin, plecanatide, methylnaltrexone bromide and PEG-3350, electrolytes and ascorbate for oral solution – will be accessible on Digestive Disease Week®'s ePosters and ePapers free, online portal beginning Saturday, May 2, 2020.

• 

  Inflammatory Bowel Disease Insight Report: Current Therapies, Drug Pipeline and Outlook

  11/19/2019

  Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.

• Salix Announces Issuance of an Additional XIFAXAN® Patent

  10/31/2019

  Additional Use Patent Covering IBS Strengthens Patent Portfolio

• Salix Pharmaceuticals Announces Inaugural Scholarship Program To Commemorate Its 30th Anniversary

  10/30/2019

  Applications For The Salix Gastrointestinal Health Scholars Program Will Be Accepted Beginning Nov. 1, 2019

• Bausch Health Provides APRISO® Intellectual Property Litigation Update

  7/31/2019

  Bausch Health Companies Inc. along with its wholly owned subsidiary, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, have agreed to resolve the outstanding intellectual property litigation with Teva Pharmaceuticals USA, Inc. regarding APRISO® extended-release capsules 0.375g.

• Salix Pharmaceuticals Pledges Annual $100,000 Scholarship Program To Outstanding Students Living with GI Disease

  5/17/2019

  Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, today announced that it will launch the Salix Gastrointestinal Health Scholars Program,

• Salix Pharmaceuticals Marks 30-Year Anniversary With Largest Showing Of Data At Digestive Disease Week

  5/14/2019

  Breadth of Data Reinforces Decades of Commitment to Healthcare Providers and Patients